Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 9/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30453166 | 1.00 | CYP11B1 (0.47) | CYP11B1CYP11B2CYP19A1KDM4EHTT | |
| SCHEMBL29248951 | 0.89 | CYP11B1 (0.57) | CYP11B1CYP11B2CYP19A1KDM4EGAA | |
| SCHEMBL30546846 | 0.89 | CYP11B1 (0.57) | CYP11B1CYP11B2CYP19A1KDM4EGAA | |
| SCHEMBL30546888 | 0.88 | CYP11B1 (0.42) | CYP11B1CYP11B2CYP19A1KDM4EHTT | |
| SCHEMBL24257687 | 0.88 | CYP11B1 (0.42) | CYP11B1CYP11B2CYP19A1KDM4EHTT | |
| SCHEMBL24257777 | 0.87 | MAPT (0.42) | KDM4EHTTGAAHSD17B10ALDH1A1 | |
| SCHEMBL24257768 | 0.84 | SQOR (0.42) | CYP11B1CYP11B2KDM4EHTTHSD17B10 | |
| SCHEMBL24257771 | 0.82 | GRM5 (0.42) | KDM4EMAPTHPGDMAPK1TP53 | |
| SCHEMBL24257769 | 0.82 | C5AR1 (0.41) | CYP11B1CYP11B2KDM4EHTTHSD17B10 | |
| SCHEMBL30546869 | 0.82 | C5AR1 (0.41) | CYP11B1CYP11B2KDM4EHTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4196466-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022036188-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022036188-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | CYP11B1 809/4885CYP11B2 703/4885CYP19A1 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.